Oxidative stress and cell membranes in the pathogenesis of Alzheimer's disease

Physiology

Volumn 26, Issue 1, 2011, Pages 54-69

  Axelsen, Paul H ^a   Komatsu, Hiroaki ^a   Murray, Ian V J ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b TEXAS A M COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; ION CHANNEL;

ALZHEIMER DISEASE; ANIMAL; BRAIN; CELL MEMBRANE; HUMAN; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; PHYSIOLOGY; REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN; CELL MEMBRANE; HUMANS; ION CHANNELS; OXIDATIVE STRESS;

EID: 79955064557     PISSN: 15489213     EISSN: 15489221     Source Type: Journal    
DOI: 10.1152/physiol.00024.2010     Document Type: Review

References (364)

1. Abdul HM, Butterfield DA. Protection against amyloid beta-peptide (1-42)-induced loss of phospholipid asymmetry in synaptosomal membranes by tricyclodecan-9-xanthogenate (D609) and ferulic acid ethyl ester: implications for Alzheimer's disease. BBA Mol Basis Dis 1741: 140-48, 2005.
2. Aisenbrey C, Borowik T, Bystrom R, Bokvist M, Lindstrom F, Misiak H, Sani MA, Grobner G. How is protein aggregation in amyloidogenic diseases modulated by biological membranes? Eur Biophys J Biophys Lett 37: 247-255, 2008.
3. Aizawa Y, Fukatsu R, Takamaru Y, Tsuzuki K, Chiba H, Ko-bayashi K, Fujii N, Takahata N. Amino-terminus truncated apolipoprotein E is the major species in amyloid deposits in Alzheimer's disease affected brains: a possible role for apo-lipoprotein E in Alzheimer's disease. Brain Res 768: 208-214, 1997.
4. Aleshkov S, Abraham CR, Zannis V I. Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1-40). Relevance to Alzheimer's disease. Biochemistry 36: 10571-10580, 1997.
5. Ali FE, Separovic F, Barrow CJ, Cherny RA, Fraser F, Bush AI, Masters CL, Barnham KJ. Methionine regulates copper/hydrogen peroxide oxidation products of A beta. J Pept Sci 11: 353-360, 2005.
6. Ali FE, Separovic F, Barrow CJ, Yao SG, Barnham KJ. Copper and zinc mediated oligomerisation of A beta peptides. Int J Pept Res Ther 12: 153-164, 2006.
7. Ando Y, Brannstrom T, Uchida K, Nyhlin N, Nasman B, Suhr O, Yamashita T, Olsson T, El Salhy M, Uchino M, Ando M. Histochemical detection of 4-hydroxynonenal protein in Alzheimer amyloid. J Neurol Sci 156: 172-176, 1998.
8. Arispe N. Architecture of the Alzheimer's A beta P ion channel pore. J Membrane Biol 197: 33-48, 2004.
9. Arispe N, Diaz JC, Simakova OA. 3 Ion channels. Prospects for treating Alzheimer's disease with A3 channel blockers. BBA Biomembranes 1768: 1952-1965, 2007.
10. Arispe N, Pollard HB, Rojas E. Giant multilevel cation channels formed by Alzheimer-disease amyloid beta-protein [A-Beta-P-(1-40)] in bilayer-membranes. Proc Natl Acad Sci USA 90: 10573-10577, 1993.
11. 2+ interaction with Alzheimer amyloid beta protein calcium channels. Proc Natl Acad Sci USA 93: 1710-1715, 1996.
12. Arispe N, Rojas E, Pollard HB. Alzheimer-disease amyloid beta-protein forms calcium channels in bilayer-membranes: blockade by tromethamine and aluminum. Proc Natl Acad Sci USA 90: 567-571, 1993.
13. Arlt S, Beisiegel U, Kontush A. Lipid peroxidation in neurodegeneration: new insights into Alzheimer's disease. Curr Opin Lipid 13: 289-294, 2002.
14. Arneson KO, Roberts LJ. Measurement of products of docosahexaenoic acid peroxidation, neu-roprostanes, and neurofurans. Lipidomics Bioactive Lipids 433: 127-143, 2007.
15. Atwood CS, Huang XD, Khatri A, Scarpa RC, Kim YS, Moir RD, Tanzi RE, Roher AE, Bush AI. Copper catalyzed oxidation of alzheimer A beta. Cell Mol Biol 46: 777-783, 2000.
16. Atwood CS, Obrenovich ME, Liu TB, Chan H, Perry G, Smith MA, Martins RN. Amyloid-beta: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-beta. Brain Res Rev 43: 1-16, 2003.
17. Atwood CS, Perry G, Zeng H, Kato Y, Jones WD, Ling KQ, Huang XD, Moir RD, Wang DD, Sayre LM, Smith MA, Chen SG, Bush AI. Copper mediates dityrosine cross-linking of Alzheimer's amyloid-beta. Biochemistry 43: 560-568, 2004.
18. Bales KR, Verina T, Cummins DJ, Du YS, Dodel TC, Saura J, Fishman CE, DeLong CA, Piccardo P, Petegnief V, Ghetti B, Paul SM. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 96: 15233-15238, 1999.
19. Bales KR, Verina T, Dodel RC, Du YS, Altstiel L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ, Piccardo P, Ghetti B, Paul SM. Lack of apolipoprotein E dramatically reduces amyloid beta- peptide deposition. Nat Gen 17: 263-264, 1997.
20. Ballatore C, Lee VMY, Trojanowski JQ. Tau-me-diated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 8: 663-672, 2007.
21. Barnham KJ, Ciccotosto GD, Tickler AK, Ali FE, Smith DG, Williamson NA, Lam YH, Carrington D, Tew D, Kocak G, Volitakis I, Separovic F, Barrow CJ, Wade JD, Masters CL, Cherny RA, Curtain CC, Bush AI, Cappai R. Neurotoxic, redox-com-petent Alzheimer's beta-amyloid is released from lipid membrane by methionine oxidation. J Biol Chem 278: 42959-42965, 2003.
22. Barnham KJ, Haeffner F, Ciccotosto GD, Curtain CC, Tew D, Beyreuther K, Carrington D, Masters CL, Cherny RA, Cappai R, Bush AI. Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease 3-amyloid. FASEB J 18: 1427-1429, 2004.
23. Baruch-Suchodolsky R, Fischer B. Soluble amyloid beta(1-28)-copper(I)/copper(II)/iron(II) complexes are potent antioxidants in cell-free systems. Biochemistry 47: 7796-7806, 2008.
24. Baruch-Suchodolsky R, Fischer B. Aβ40, either soluble or aggregated, is a remarkably potent antioxidant in cell-free oxidative systems. Biochemistry 48: 4354-4370, 2009.
25. Baudier J, Cole RD. Phosphorylation of tau-pro-teins to a state like that in Alzheimers brain is catalyzed by a calcium calmodulin-dependent ki-nase and modulated by phospholipids. J Biol Chem 262: 17577-17583, 1987.
26. Baumann MH, Kallijarvi J, Lankinen H, Soto C, Haltia M. Apolipoprotein E includes a binding site which is recognized by several amyloido-genic polypeptides. Biochem J 349: 77-84, 2000.
27. Behl C, Davis JB, Lesley R, Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 77: 817-827, 1994.
28. Berthon G. Does human beta A4 exert a protective function against oxidative stress in Alzheimer's disease? Med Hypotheses 54: 672-677, 2000.
29. Bielicki JK, Oda MN. Apolipoprotein A-I-Milano and apolipoprotein A-I-Paris exhibit an antioxi-dant activity distinct from that of wild-type apo-lipoprotein A-I. Biochemistry 41: 2089-2096, 2002.
30. Bieschke J, Zhang Q, Powers ET, Lerner RA, Kelly JW. Oxidative metabolites accelerate Alzheimer's amyloidogenesis by a two-step mechanism, eliminating the requirement for nucleation. Biochemistry 44: 4977-4983, 2005.
31. Bishop GM, Robinson SR. The amyloid paradox: amyloid-beta-metal complexes can be neuro-toxic and neuroprotective. Brain Pathol 14: 448- 452, 2004.
32. Bitan G, Tarus B, Vollers SS, Lashuel HA, Con-dron MM, Straub JE, Teplow DB. A molecular switch in amyloid assembly: Met(35) and amyloid beta-protein oligomerization. J Am Chem Soc 125: 15359-15365, 2003.
33. Bokvist M, Lindstrom F, Watts A, Grobner G. Two types of Alzheimer's beta-amyloid (1-40) peptide membrane interactions: aggregation preventing transmembrane anchoring versus accelerated surface fibril formation. J Mol Biol 335: 1039-1049, 2004.
34. Boyd-Kimball D, Castegna A, Sultana R, Poon HF, Petroze R, Lynn BC, Klein JB, Butterfield DA. Proteomic identification of proteins oxidized by A beta(1-42) in synaptosomes: implications for Alzheimer's disease. Brain Res 1044: 206-215, 2005.
35. Brezesinski G, Maltseva E, Mohwald H. Adsorption of amyloid beta (1-40) peptide at liquid interfaces. Z Phys Chem 221: 95-111, 2007.
36. Brosche T, Platt D. Mini-review: The significance of plasmalogens in defense against oxidative damage. Exp Gerontol 33: 363-369, 1998.
37. Bruenner BA, Jones AD, German JB. Direct characterization of protein adducts of the lipid-per-oxidation product 4-hydroxy-2-nonenal using electrospray mass-spectrometry. Chem Res Tox 8: 552-559, 1995.
38. Bryleva EY, Rogers MA, Chang CCY, Buen F, Harris BT, Rousselet E, Seidah NG, Oddo S, LaFerla FM, Spencer TA, Hickey WF, Chang TY. ACAT1 gene ablation increases 24(S)-hydroxy-cholesterol content in the brain and ameliorates amyloid pathology in mice with AD. Proc Natl Acad Sci USA 107: 3081-3086, 2010.
39. Bush AI. The metallobiology of Alzheimer's disease. Trends Neurosci 26: 207-214, 2003.
40. Butterfield DA. Amyloid beta-peptide (1-42)-in-duced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. Free Radic Res 36: 1307- 1313, 2002.
41. Butterfield DA. Proteomics: a new approach to investigate oxidative stress in Alzheimer's disease brain. Brain Res 1000: 1-7, 2004.
42. Butterfield DA, Boyd-Kimball D. Amyloid beta-peptide(1-42) contributes to the oxidative stress and neurodegeneration found in Alzheimer disease brain. Brain Pathol 14: 426-432, 2004.
43. Butterfield DA, Boyd-Kimball D. The critical role of methionine 35 in Alzheimer's amyloid-beta-peptide (1-42)-induced oxidative stress and neu-rotoxicity. Biochim Biophys Acta 1703: 149-156, 2005.
44. Butterfield DA, Boyd-Kimball D, Castegna A. Pro-teomics in Alzheimer's disease: insights into potential mechanisms of neurodegeneration. J Neurochem 86: 1313-1327, 2003.
45. Butterfield DA, Bush AI. Alzheimer's amyloid be-ta-peptide (1-42): involvement of methionine residue 35 in the oxidative stress and neurotoxicity properties of this peptide. Neurobiol Aging 25: 563-568, 2004.
46. Butterfield DA, Castegna A, Lauderback CM, Drake J. Evidence that amyloid beta-peptide-in-duced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. Neurobiol Aging 23: 655-664, 2002.
47. Butterfield DA, Galvan V, Lange MB, Tang HD, Sowell RA, Spilman P, Fombonne J, Gorostiza O, Zhang JL, Sultana R, Bredesen DE. In vivo oxida-tive stress in brain of Alzheimer disease trans-genic mice: requirement for methionine 35 in amyloid beta-peptide of APP. Free Radic Biol Med 48: 136-144, 2010.
48. Butterfield DA, Hensley K, Harris M, Mattson MP, Carney JM. Beta-amyloid peptide free-radical fragments initiate synaptosomal lipoperoxida-tion in a sequence-specific fashion: implications to Alzheimers-disease. Biochem Biophys Res Commun 200: 710-715, 1994.
49. Butterfield DA, Kanski J. Methionine residue 35 is critical for the oxidative stress and neurotoxic properties of Alzheimer's amyloid beta-peptide 1-42. Peptides 23: 1299-1309, 2002.
50. Butterfield DA, Lauderback CM. Lipid peroxida-tion and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic Biol Med 32: 1050-1060, 2002.
51. Butterfield DA, Reed T, Newman SF, Sultana R. Roles of amyloid beta-peptide-associated oxida-tive stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radic Biol Med 43: 658-677, 2007.
52. Calingasan NY, Uchida K, Gibson GE. Protein-bound acrolein: a novel marker of oxidative stress in Alzheimer's disease. J Neurochem 72: 751-756, 1999.
53. Calon F, Cole G. Neuroprotective action of omega-3 polyunsaturated fatty acids against neurodegenerative diseases: evidence from animal studies. Prost Leuk Essen Fatty Acids 77: 287-293, 2007.
54. Calon F, Lim GP, Morihara T, Yang FS, Ubeda O, Salem N, Frautschy SA, Cole GM. Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer's disease. Eur J Neurosci 22: 617-626, 2005.
55. Calon F, Lim GP, Yang FS, Morihara T, Teter B, Ubeda O, Rostaing P, Triller A, Salem N, Ashe KH, Frautschy SA, Cole GM. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 43: 633-645, 2004.
56. Capone R, Quiroz FG, Prangkio P, Saluja I, Sauer AM, Bautista MR, Turner RS, Yang J, Mayer M. Amyloid-beta-induced ion flux in artificial lipid bilayers and neuronal cells: resolving a controversy. Neurotox Res 16: 1-13, 2009.
57. Castegna A, Aksenov M, Aksenova M, Thong-boonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, Butterfield DA. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part 1: creatine kinase bb, glutamine synthase, and ubiquitin carboxy-termi-nal hydrolase L-1. Free Radic Biol Med 33: 562-571, 2002.
58. Castegna A, Aksenov M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, Butterfield DA. Proteomic identification of oxida-tively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. J Neurochem 82: 1524-1532, 2002.
59. Castegna A, Lauderback CM, Mohmmad-Abdul H, Butterfield DA. Modulation of phospholipid asymmetry in synaptosomal membranes by the lipid peroxidation products, 4-hydroxynonenal and acrolein: implications for Alzheimer's disease. Brain Res 1004: 193-197, 2004.
60. Castegna A, Thongboonkerd V, Klein JB, Lynn B, Markesbery WR, Butterfield DA. Proteomic identification of nitrated proteins in Alzheimer's disease brain. J Neurochem 85: 1394-1401, 2003.
61. Castellani RJ, Perry G, Harris PLR, Cohen ML, Sayre LM, Salomon RG, Smith MA. Advanced lipid peroxidation end-products in Alexander's disease. Brain Res 787: 15-18, 1998.
62. Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Ann Rev Neurosci 26: 267-298, 2003.
63. Chauhan A, Ray I, Chauhan VPS. Interaction of amyloid beta-protein with anionic phospholipids: possible involvement of Lys(28) and C-terminus aliphatic amino acids. Neurochem Res 25: 423- 429, 2000.
64. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, Mclean CA, Barnham KJ, Volitakis I, Fraser FW, Kim YS, Huang XD, Goldstein LE, Moir RD, Lim JT, Beyreuther K, Zheng H, Tanzi RE, Masters CL, Bush AI. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease trans-genic mice. Neuron 30: 665-676, 2001.
65. Cherny RA, Legg JT, Mclean CA, Fairlie DP, Huang XD, Atwood CS, Beyreuther K, Tanzi RE, Masters CL, Bush AI. Aqueous dissolution of Alzheimer's disease A beta amyloid deposits by bio-metal depletion. J Biol Chem 274: 23223-23228, 1999.
66. Chi EY, Ege C, Winans A, Majewski J, Wu GH, Kjaer K, Lee KYC. Lipid membrane templates the ordering and induces the fibrillogenesis of Alzheimer's disease amyloid-beta peptide. Proteins 72: 1-24, 2008.
67. Chi EY, Frey SL, Lee KYC. Ganglioside GM1-mediated amyloid-beta fibrillogenesis and membrane disruption. Biochemistry 46: 1913-1924, 2007.
68. Choo-Smith LP, Garzon-Rodriguez W, Glabe CG, Surewicz WK. Acceleration of amyloid fibril formation by specific binding of Abeta-(1-40) peptide to ganglioside-containing membrane vesicles. J Biol Chem 272: 22987-22990, 1997.
69. Choo-Smith LP, Surewicz WK. The interaction between Alzheimer amyloid beta(1-40) peptide and ganglioside GM1-containing membranes. FEBS Lett 402: 95-98, 1997.
70. Ciccotosto GD, Tew D, Curtain CC, smith D, Car-rington D, Masters CL, Bush AI, Cherny RA, Cap-pai R, Barnham KJ. Enhanced toxicity and cellular binding of a modified amyloid beta peptide with a methionine to valine substitution. J Biol Chem 279: 28425-42538, 2004.
71. Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Menn-erick S, Holtzman DM. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 48: 913-922, 2005.
72. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH. Natural oligomers of the amyloid-protein specifically disrupt cognitive function. Nat Neurosci 8: 79-84, 2005.
73. Corder EH, Saunders AM, Strittmatter WJ, Sch-mechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericakvance MA. Gene dose of apo-lipoprotein-E type-4 allele and the risk of Al-zheimers-disease in late-onset families. Science 261: 921-923, 1993.
74. Cordy JM, Hooper NM, Turner AJ. The involvement of lipid rafts in Alzheimer's disease. Mol Membr Biol 23: 111-122, 2006.
75. Cuajungco MP, Goldstein LE, Nunomura A, Smith MA, Lim JT, Atwood CS, Huang X, Farrag YW, Perry G, Bush AI. Evidence that the β-amy-loid plaques of Alzheimer's disease represent the redox-silencing and entombment of abeta by zinc. J Biol Chem 275: 19439-19442, 2000.
76. Curtain CC, Ali F, Volitakis I, Cherny RA, Norton RS, Beyreuther K, Barrow CJ, Masters CL, Bush AI, Barnham KJ. Alzheimer's eisease amyloid-beta binds copper and zinc to generate an allosteri-cally ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J Biol Chem 276: 20466-20473, 2001.
77. Curtain CC, Ali FE, Smith DG, Bush AI, Masters CL, Barnham KJ. Metal ions, pH, and cholesterol regulate the interactions of Alzheimer's disease amyloid-beta peptide with membrane lipid. J Biol Chem 278: 2977-2982, 2003.
78. Cutler RG, Kelly J, Storie K, Pedersen WA, Tam-mara A, Hatanpaa K, Troncoso JC, Mattson MP. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci USA 101: 2070-2075, 2004.
79. D'Errico G, Vitiello G, Ortona O, Tedeschi A, Ramunno A, D'Ursi AM. Interaction between Alzheimer's A beta(25-35) peptide and phospholipid bilayers: the role of cholesterol. Biochim Biophys Acta 1778: 2710-2716, 2008.
80. Dalle-Donne I, Rossi R, Giustarini D, Gagliano N, Lusini L, Milzani A, Di Simplicio P, Colombo R. Actin carbonylation: from a simple marker of protein oxidation to relevant signs of severe functional impairment. Free Radic Biol Med 31: 1075-1083, 2001.
81. Dante S, Hauss T, Brandt A, Dencher NA. Membrane fusogenic activity of the Alzheimer's peptide A beta(1-42) demonstrated by small-angle neutron scattering. J Mol Biol 376: 393-404, 2008.
82. Dante S, Hauss T, Dencher NA. Insertion of externally administered amyloid beta peptide 25-35 and perturbation of lipid bilayers. Biochemistry 42: 13667-13672, 2003.
83. de Planque MRR, Raussens V, Contera SA, Rijkers DTS, Liskamp RMJ, Ruysschaert JM, Ryan JF, Sepa-rovic F, Watts A. beta-sheet structured beta-am-yloid(1-40) perturbs phosphatidylcholine model membranes. J Mol Biol 368: 982-997, 2007.
84. DeMar JC, Ma KZ, Bell JM, Rapoport SI. Half-lives of docosahexaenoic acid in rat brain phospholipids are prolonged by 15 weeks of nutritional deprivation of n-3 polyunsaturated fatty acids. J Neurochem 91: 1125-1137, 2004.
85. Demuro A, Parker I, Stutzmann GE. Calcium signaling and amyloid toxicity in Alzheimer's disease. J Biol Chem 285: 12463-12468, 2010.
86. Deshpande A, Kawai H, Metherate R, Glabe CG, Busciglio J. A role for synaptic zinc in activity-dependent A beta oligomer formation and accumulation at excitatory synapses. J Neurosci 29: 4004-4015, 2009.
87. Devanathan S, Salamon Z, Lindblom G, Grobner G, Tollin G. Effects of sphingomyelin, cholesterol and zinc ions on the binding, insertion and aggregation of the amyloid A beta(1-40) peptide in solid-supported lipid bilayers. FEBS J 273: 1389-1402, 2006.
88. Diaz JC, Simakova O, Jacobson KA, Arispe N, Pollard HB. Small molecule blockers of the Alzheimer A beta calcium channel potently protect neurons from A beta cytotoxicity. Proc Natl Acad Sci USA 106: 3348-3353, 2009.
89. Dikalov SI, Vitek MP, Maples KR, Mason RP. Amyloid beta peptides do not form peptide-derived free radicals spontaneously, but can enhance metal-catalyzed oxidation of hydroxylamines to nitroxides. J Biol Chem 274: 9392-9399, 1999.
90. Donnelly PS, Xiao ZG, Wedd AG. Copper and Alzheimer's disease. Curr Opin Chem Biol 11: 128-133, 2007.
91. Drake J, Link CD, Butterfield DA. Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid beta-peptide (1-42) in a transgenic Caenorhabditis elegans model. Neu-robiol Aging 24: 415-420, 2003.
92. Drew SC, Noble CJ, Masters CL, Hanson GR, Barnham KJ. Pleomorphic copper coordination by Alzheimer's disease amyloid-beta peptide. J Am Chem Soc 131: 1195-1207, 2009.
93. Durell SR, Guy HR, Arispe N, Rojas E, HB Pollard.Theoretical-models of the ion-channel structure of amyloid beta-protein. Biophys J 67: 2137-2145, 1994.
94. Ege C, Lee KYC. Insertion of Alzheimer's A beta 40 peptide into lipid monolayers. Biophys J 87: 1732-1740, 2004.
95. Ehehalt R, Keller P, Haass C, Thiele C, Simons K. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol 160: 113-123, 2003.
96. Eliezer D. Amyloid ion channels: a porous argument or a thin excuse? J Gen Physiol 128: 631- 633, 2006.
97. Esterbauer H, Benedetti A, LANG J,R Fulceri, G Fauler, M Comporti. Studies on the mechanism of formation of 4-hydroxynonenal during micro-somal lipid-peroxidation. Biochim Biophys Acta 876: 154-166, 1986.
98. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonal-dehyde and related aldehydes. Free Radic Biol Med 11: 81-128, 1991.
99. Evans KC, Berger EP, Cho CG, Weisgraber KH, Lansbury PT. Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. Proc Natl Acad Sci USA 92: 763-767, 1995.
100. Faller P, Hureau C. Bioinorganic chemistry of copper and zinc ions coordinated to amyloid-beta peptide. Dalton Trans 21: 1080-1094, 2009.
101. Farooqui AA, Horrocks LA. Plasmalogens: Workhorse lipids of membranes in normal and injured neurons and glia. Neuroscientist 7: 232-245, 2001.
102. Farooqui AA, Rapoport SI, Horrocks LA. Membrane phospholipid alterations in Alzheimer's disease: Deficiency of ethanolamine plasmalo-gens. Neurochem Res 22: 523-527, 1997.
103. Friedland RP. Fish consumption and the risk of Alzheimer disease - Is it time to make dietary recommendations? Arch Neurol 60: 923-924, 2003.
104. Galbusera C, Facheris M, Magni F, Galimberti G, Sala G, Tremolada L, Isella V, Guerini FR, Appol-lonio I, Galli-Kienle M, Ferrarese C. Increased susceptibility to plasma lipid peroxidation in Alzheimer disease patients. Curr Alzheimer Res 1: 103-109, 2004.
105. Garzon-Rodriguez W, Yatsimirsky AK, Glabe CG. Binding of Zn(II), Cu(II), and Fe(II) ions to Alzheimer's A beta peptide studied by fluorescence. Bioorg Med Chem Lett 9: 2243-2248, 1999.
106. Gehman JD, O'Brien CC, Shabanpoor F, Wade JD, Separovic F. Metal effects on the membrane interactions of amyloid-beta peptides. Eur Bio-phys J Biophys Lett 37: 333-344, 2008.
107. Ghezzi P, Bonetto V. Redox proteomics: Identification of oxidatively, modified proteins. Pro-teomics 3: 1145-1153, 2003.
108. Ghribi O, Larsen B, Schrag M, Herman MM. High cholesterol content in neurons increases BACE, beta-amyloid, and phosphorylated tau levels in rabbit hippocampus. Exp Neurol In Press: 2006.
109. Giles GI, Jacob C. Reactive sulfur species: an emerging concept in oxidative stress. Biol Chem 383: 375-388, 2002.
110. Ginsberg L, Rafique S, Xuereb JH, Rapoport SI, Gershfeld NL. Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Al-zheimers-disease brain. Brain Res 698: 223-226, 1995.
111. Ginsberg L, Xuereb JH, Gershfeld NL. Membrane instability, plasmalogen content, and Alzheimer's disease. J Neurochem 70: 2533-2538, 1998.
112. Goodenowe DB, Cook LL, Liu J, Lu Y, Jayas-inghe DA, Ahiahonu PWK, Heath D, Yamazaki Y, Flax J, Krenitsky KF, Sparks DL, Lerner A, Friedland RP, Kudo T, Kamino K, Morihara T, Takeda M, Wood PL. Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer's disease and dementia. J Lipid Res 48: 2485-2498, 2007.
113. Gorbenko GP, Kinnunen PKJ. The role of lipid-protein interactions in amyloid-type protein fibril formation. Chem Phys Lipids 141: 72-82, 2006.
114. Green JD, Kreplak L, Goldsbury C, Blatter XL, Stolz M, Cooper GS, Seelig A, Kist-Ler J, Aebi U. Atomic force microscopy reveals defects within mica supported lipid bilayers induced by the amyloidogenic human amylin peptide. J Mol Biol 342: 877-887, 2004.
115. Gylys KH, Fein JA, Yang F, Miller CA, Cole GM. Increased cholesterol in A beta-positive nerve terminals from Alzheimer's disease cortex. Neu-robiol Aging 28: 8-17, 2007.
116. Haeffner F, Smith DG, Barnham KJ, Bush AI. Model studies of cholesterol and ascorbate oxidation by copper complexes: relevance to Alzheimer's disease beta-amyloid metallochemistry. J Inorg Biochem 99: 2403-2422, 2005.
117. Hahnel D, Beyer K, Engelmann B. Inhibition of peroxyl radical-mediated lipid oxidation by plas-malogen phospholipids and alpha-tocopherol. Free Radic Biol Med 27: 1087-1094, 1999.
118. Hahnel D, Huber T, Kurze V, Beyer K, Engelmann B. Contribution of copper binding to the inhibition of lipid oxidation by plasmalogen phospho-lipids. Biochem J 340: 377-383, 1999.
119. Han X. Lipid alterations in the earliest clinically recognizable stage of Alzheimer's disease: implication of the role of lipids in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 2: 65-77, 2005.
120. Han XL, Holtzman DM, McKeel DW. Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. J Neurochem 77: 1168-1180, 2001.
121. Han XL, Holtzman DM, McKeel DW, Kelley J, Morris JC. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J Neurochem 82: 809-818, 2002.
122. Hansen LM, Masliah E, Galasko D, Terry RD. Plaque-only Alzheimer-disease is usually the Lewy body variant, and vice-versa. J Neuropath Exp Neurol 52: 648-654, 1993.
123. Hardy J, Allsop D. Amyloid deposition as the central event in the etiology of Alzheimers-dis-ease. Trends Pharmacol Sci 12: 383-388, 1991.
124. Hardy JA, Higgins GA. Alzheimers-disease: the amyloid cascade hypothesis. Science 256: 184- 185, 1992.
125. Harper JD, Wong SS, Lieber CM, Lansbury PT. Observation of metastable A beta amyloid protofibrils by atomic force microscopy. Chem Biol 4: 119-125, 1997.
126. Hashimoto M, Tanabe Y, Fujii Y, Kikuta T, Shibata H, Shido O. Chronic administration of docosa-hexaenoic acid ameliorates the impairment of spatial cognition learning ability in amyloid beta-infused rats. J Nutr 135: 549-555, 2005.
127. Hayashi H, Kimura N, Yamaguchi H, Hasegawa K, Yokoseki T, Shibata M, Yamamoto N, Michikawa M, Yoshikawa Y, Terao K, Matsuzaki K, Lemere CA, Selkoe DJ, Naiki H, Yanagisawa K. A seed for Alzheimer amyloid in the brain. J Neurosci 24: 4894-4902, 2004.
128. Hensley K, Carney JM, Mattson MP, Aksenova M, Harris M, Wu JF, Floyd RA, Butterfield DA. A model for beta-amyloid aggregation and neuro-toxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc Natl Acad Sci USA 91: 3270-3274, 1994.
129. Hensley K, Hall N, Subramaniam R, Cole P, Harris M, Aksenov M, Aksenova M, Gabbita SP, Wu JF, Carney JM, Lovell MA, Markesbery WR, Butter-field DA. Brain regional correspondence between Alzheimers-disease histopathology and biomarkers of protein oxidation. J Neurochem 65: 2146-2156, 1995.
130. Hertel C, Terzi E, Hauser N, Jakob-Rotne R, Seelig J, Kemp JA. Inhibition of the electrostatic interaction between beta-amyloid peptide and membranes prevents beta-amyloid-induced tox-icity. Proc Natl Acad Sci USA 94: 9412-9416, 1997.
131. Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, Johnson AB, Kress Y, Vinters HV, Tabaton M, Shimohama S, Cash AD, Siedlak SL, Harris PLR, Jones PK, Petersen RB, Perry G, Smith MA. Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 21: 3017-3023, 2001.
132. Hou LM, Kang I, Marchant RE, Zagorski MG. Methionine 35 oxidation reduces fibril assembly of the amyloid A beta-(1-42) peptide of Alzheimer's disease. J Biol Chem 277: 40173-40176, 2002.
133. Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, Malinow R. AMPAR removal underlies A beta-induced synaptic depression and dendritic spine loss. Neuron 52: 831-843, 2006.
134. Huang XD, Atwood CS, Hartshorn MA, Multhaup G, Goldstein LE, Scarpa RC, Cuajungco MP, Gray DN, Lim J, Moir RD, Tanzi RE, Bush AI. The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 38: 7609-7616, 1999.
135. Huang XD, Cuajungco MP, Atwood CS, Hartshorn MA, Tyndall JDA, Hanson GR, Stokes KC, Leopold M, Multhaup G, Goldstein LE, Scarpa RC, Saunders AJ, Lim J, Moir RD, Glabe C, Bowden EF, Masters CL, Fairlie DP, Tanzi RE, Bush AI. Cu(II) potentiation of Alzheimer A beta neurotoxicity: correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem 274: 37111-37116, 1999.
136. Hung LW, Ciccotosto GD, Giannakis E, Tew DJ, Perez K, Masters CL, Cappai R, Wade JD, Barn-ham KJ. Amyloid-beta peptide (A beta) neurotoxicity is modulated by the rate of peptide aggregation: A beta dimers and trimers correlate with neurotoxicity. J Neurosci 28: 11950-11958, 2008.
137. Hutter-Paier B, Huttunen HJ, Puglielli L, Eckman CB, Kim DY, Hofmeister A, Moir RD, Domnitz SB, Frosch MP, Windisch M, Kovacs DM. The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer's disease. Neuron 44: 227-238, 2004.
138. Igarashi M, Gao F, Kim HW, Ma KZ, Bell JM, Rapoport SI. Dietary n-6 PUFA deprivation for 15 weeks reduces arachidonic acid concentrations while increasing n-3 PUFA concentrations in organs of post-weaning male rats. BBA Mol Cell Biol Lipids 1791: 132-139, 2009.
139. Inoue K, Garner C, Ackermann BL, Oe T, Blair IA. Liquid chromatography/tandem mass spectrometry characterization of oxidized amyloid beta peptides as potential biomarkers of Alzheimer's disease. Rapid Commun Mass Spectrom 20: 911-918, 2006.
140. Isaacs AM, Senn DB, Yuan M, Shine JP, Yankner BA. Acceleration of amyloid beta -peptide aggregation by physiological concentrations of calcium. J Biol Chem 281: 27916-27923, 2006.
141. Issa AM, Mojica WA, Morton SC, Traina S, Newberry SJ, Hilton LG, Garland RH, MacLean CH. The efficacy of omega-3 fatty acids on cognitive function in aging and dementia: a systematic review. Dement Geriatr Cogn Disord 21: 88-96, 2006.
142. Jang H, Arce FT, Ramachandran S, Capone R, Azimova R, Kagan BL, Nussinov R, Lal R. Truncated β-amyloid peptide channels provide an alternative mechanism for Alzheimer's Disease and Down syndrome. Proc Natl Acad Sci USA 107: 6838-6543, 2010.
143. Jarrett JT, Berger EP, Lansbury PT. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32: 4693-4697, 1993.
144. Jeandel C, Nicolas MB, Dubois F, Nabet-Bel-leville F, Penin F, Cuny G. Lipid peroxidation and free radical scavengers in Alzheimer's disease. Gerontology 35: 275-282, 1989.
145. Ji SR, Wu Y, Sui SF. Cholesterol is an important factor affecting the membrane insertion of beta-amyloid peptide (A beta 1-40), which may potentially inhibit the fibril formation. J Biol Chem 277: 6273-6279, 2002.
146. Johansson AS, Garlind A, Berglind-Dehlin F, Karlsson G, Edwards K, Gellerfors P, Ekholm-Pettersson F, Palmblad J, Lannfelt L. Docosa-hexaenoic acid stabilizes soluble amyloid-beta protofibrils and sustains amyloid-beta-induced neurotoxicity in vitro. FEBS J 274: 990-1000, 2007.
147. Kagan BL, Azimov R, Azimova R. Amyloid peptide channels. J Membrane Biol 202: 1-10, 2004.
148. Kakio A, Nishimoto S, Yanagisawa K, Kozutsumi Y, Matsuzaki K. Cholesterol-dependent formation of GM1 ganglioside-bound amyloid beta-protein, an endogenous seed for Alzheimer amyloid. J Biol Chem 276: 24985-24990, 2001.
149. Kakio A, Nishimoto S, Yanagisawa K, Kozutsumi Y, Matsuzaki K. Interactions of amyloid beta-protein with various gangliosides in raft-like membranes: importance of GM1 ganglioside-bound form as an endogenous seed for Alzheimer amyloid. Biochemistry 41: 7385-7390, 2002.
150. Kakio A, Nishimoto SI, Kozutsumi Y, Matsuzaki K. Formation of a membrane-active form of amyloid beta-protein in raft-like model membranes. Biochem Biophys Res Commun 303: 514-518, 2003.
151. Kakio A, Yano Y, Takai D, Kuroda Y, Matsumoto O, Kozutsumi Y, Matsuzaki K. Interaction between amyloid beta-protein aggregates and membranes. J Pept Sci 10: 612-621, 2004.
152. Kalvodova L, Kahya N, Schwille P, Ehehalt R, Verkade P, Drechsel D, Simons K. Lipids as modulators of proteolytic activity of BACE: involvement of cholesterol, glycosphingolipids, and anionic phospholipids in vitro. J Biol Chem 280: 36815-36823, 2005.
153. Karr JW, Szalai VA. Cu(II) binding to monomeric, oligomeric, and fibrillar forms of the Alzheimer's disease amyloid-beta peptide. Biochemistry 47: 5006-5016, 2008.
154. Kayed R, Sokolov Y, Edmonds B, McIntire TM, Milton SC, Hall JE, Glabe CG. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem 279: 46363-46366, 2004.
155. Kelly BL, Ferreira A. Beta-amyloid-induced dy-namin 1 degradation is mediated by N-methyl-D-aspartate receptors in hippocampal neurons. J Biol Chem 281: 28079-28089, 2006.
156. Khaselev N, Murphy RC. Susceptibility of plasme-nyl glycerophosphoethanolamine lipids containing arachidonate to oxidative degradation. Free Radic Biol Med 26: 275-284, 1999.
157. Khaselev N, Murphy RC. Peroxidation of arachidonate containing plasmenyl glycerophosphocho-line: facile oxidation of esterified arachidonate at carbon-5. Free Radic Biol Med 29: 620-632, 2000.
158. Khaselev N, Murphy RC. Structural characterization of oxidized phospholipid products derived from arachidonate-containing plasmenyl glycero-phosphocholine. J Lipid Res 41: 564-572, 2000.
159. Kim HY. Novel metabolism of docosahexaenoic acid in neural cells. J Biol Chem 282: 18661-18665, 2007.
160. Kitazawa M, Cheng D, LaFerla FM. Chronic copper exposure exacerbates both amyloid and tau pathology and selectively dysregulates cdk5 in a mouse model of AD. J Neurochem 108: 1550-1560, 2009.
161. Komatsu H, Liu L, Murray IV, Axelsen PH. A mechanistic link between oxidative stress and membrane mediated amyloidogenesis revealed by infrared spectroscopy. BBA Biomembranes 1768: 1913-1922, 2007.
162. Kontush A. Amyloid-β: an antioxidant that becomes a pro-oxidant and critically contributes to Alzheimer's disease. Free Radic Biol Med 31: 1120-1131, 2001.
163. Kontush A, Berndt C, Weber W, Akopyan V, Arlt S, Schippling S, Beisiegel U. Amyloid-3 is an antioxidant for lipoproteins in cerebrospinal fluid and plasma. Free Radic Biol Med 30: 119-128, 2001.
164. Kontush A, Donarski N, Beisiegel U. Resistance of human cerebrospinal fluid to in vitro oxidation is directly related to its amyloid-beta content. Free Radic Res 35: 507-517, 2001.
165. Koppaka V, Axelsen PH. Accelerated accumulation of amyloid beta proteins on oxidatively damaged lipid membranes. Biochemistry 39: 10011-10016, 2000.
166. Koppaka V, Paul C, Murray IVJ, Axelsen PH. Early synergy between Aβ42 and oxidatively damaged membranes in promoting amyloid fibril formation by Aβ40. J Biol Chem 278: 36277-36284, 2003.
167. Kremer JJ, Murphy RM. Kinetics of adsorption of beta-amyloid peptide A beta(1-40) to lipid bilayers. J Biochem Biophys Methods 57: 159-169, 2003.
168. Kremer JJ, Pallitto MM, Sklansky DJ, Murphy RM. Correlation of 3-amyloid aggregate size and hydrophobicity with decreased bilayer fluidity of model membranes. Biochemistry 39: 10309-10318, 2000.
169. Kremer JJ, Sklansky DJ, Murphy RM. Profile of changes in lipid bilayer structure caused by beta-amyloid peptide. Biochemistry 40: 8563-8571, 2001.
170. Kuczynski B, Reo NV. Evidence that plasmalogen is protective against oxidative stress in the rat brain. Neurochem Res 31: 639-656, 2006.
171. Ladu MJ, Falduto MT, Manelli AM, Reardon CA, Getz GS, Frail DE. Isoform-specific binding of apolipoprotein-E to beta-amyloid. J Biol Chem 269: 23403-23406, 1994.
172. LaFerla FM. Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat Rev Neurosci 3: 862-872, 2002.
173. Lal R, Lin H, Quist AP. Amyloid beta ion channel: 3D structure and relevance to amyloid channel paradigm. BBA Biomembranes 1768: 1966-1975, 2007.
174. Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PT. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 418: 291, 2002.
175. Lashuel HA, Lansbury PT. Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins? Q Rev Biophys 39: 167-201, 2006.
176. Lau TL, Ambroggio EE, Tew DJ, Cappai R, Masters CL, Fidelio GD, Barnham KJ, Separovic F. Amyloid-beta peptide disruption of lipid membranes and the effect of metal ions. J Mol Biol 356: 759-770, 2006.
177. Lauderback CM, Hackett JM, Huang FF, Keller JN, Szweda LI, Markesbery WR, Butterfield DA. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of A beta 1-42. J Neurochem 78: 413-416, 2001.
178. Lauderback CM, Kanski J, Hackett JM, Maeda N, Kindy MS, Butterfield DA. Apolipoprotein E modulates Alzheimer's A beta(1-42)-induced oxidative damage to synaptosomes in an allele-specific manner. Brain Res 924: 90-97, 2002.
179. Lawson JA, Rokach J, FitzGerald GA. Isopros-tanes: formation, analysis and use as indices of lipid peroxidation in vivo. J Biol Chem 274: 24441-24444, 1999.
180. Lee SH, Blair IA. Characterization of 4-oxo-2-non-enal as a novel product of lipid peroxidation. Chem Res Tox 13: 698-702, 2000.
181. Lee SJ, Liyanage U, Bickel PE, Xia WM, Lansbury PT, Kosik KS. A detergent-insoluble membrane compartment contains A beta in vivo. Nat Med 4: 730-734, 1998.
182. Lehtonen JYA, Holopainen JM, Kinnunen PKJ. Activation of phospholipase A(2) by amyloid beta-peptides in vitro. Biochemistry 35: 9407-9414, 1996.
183. Leskovjan AC, Lanzirotti A, Miller LM. Amyloid plaques in PSAPP mice bind less metal than plaques in human Alzheimer's disease. Neuroim-age 47: 1215-1220, 2009.
184. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440: 352-357, 2006.
185. Lim GP, Calon F, Morihara T, Yang FS, Teter B, Ubeda O, Salem N, Frautschy SA, Cole GM. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci 25: 3032-3040, 2005.
186. Lin H, Bhatia R, Lal R. Amyloid beta protein forms ion channels: implications for Alzheimer's disease pathophysiology. FASEB J 15: 2433-2444, 2001.
187. Liu L, Komatsu H, Murray IVJ, Axelsen PH. Promotion of amyloid 3 protein misfolding and fibril-logenesis by a lipid oxidation product. J Mol Biol 377: 1236-1250, 2008.
188. 2+-permeable AMPA receptors in synaptic plasticity and neuronal death. Trends Neurosci 30: 126-134, 2007.
189. Lorenzo A, Yuan ML, Zhang ZH, Paganetti PA, Sturchler-Pierrat C, Staufenbiel M, Mautino J, Sol V, Sommer B, Yankner BA. Amyloid beta interacts with the amyloid precursor protein: a potential toxic mechanism in Alzheimer's disease. Nat Neurosci 3: 460-464, 2000.
190. Lovell MA, Ehmann WD, Mattson MP, Markesbery WR. Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease. Neurobiol Aging 18: 457-461, 1997.
191. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 158: 47-52, 1998.
192. Lovell MA, Xie CS, Markesbery WR. Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol Aging 22: 187-194, 2001.
193. Lukiw WJ, Cui JG, Marcheselli VL, Bodker M, Botkjaer A, Gotlinger K, Serhan CN, Bazan NG. A role for docosahexaenoic acid-derived neuropro-tectin D1 in neural cell survival and Alzheimer disease. J Clin Invest 115: 2774-2783, 2005.
194. Ma JY, Yee A, Brewer HB, Das S, Potter H. Amyloid-associated proteins alpha(1)-antichymot-rypsin and apolipoprotein-E promote assembly of Alzheimer beta-protein into filaments. Nature 372: 92-94, 1994.
195. Maeba R, Sawada Y, Shimasaki H, Takahashi I, Ueta N. Ethanolamine plasmalogens protect cholesterol-rich liposomal membranes from oxidation caused by free radicals. Chem Phys Lipids 120: 145-151, 2002.
196. Maeba R, Ueta N. Ethanolamine plasmalogens prevent the oxidation of cholesterol by reducing the oxidizability of cholesterol in phospholipid bilayers. J Lipid Res 44: 164-171, 2003.
197. Mahley RW, Rall SC Jr. Apolipoprotein E: far more than a lipid transport protein. Ann Rev Genom Hum Gen 1: 507-537, 2000.
198. Manelli AM, Stine WB, Van Eldik LJ, Ladu MJ. ApoE Ap1-42 interactions. J Mol Neurosci 23: 235-246, 2004.
199. Marchesi VT. An alternative interpretation of the amyloid A beta hypothesis with regard to the pathogenesis of Alzheimer's disease. Proc Natl Acad Sci USA 102: 9093-9098, 2005.
200. Marcus DL, Thomas C, Rodriguez C, Simberkoff K, Tsai JS, Strafaci JA, Freedman ML. Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease. Exp Neurol 150: 40-44, 1998.
201. Markesbery WR. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 23: 134-147, 1997.
202. Markesbery WR, Carney JM. Oxidative alterations in Alzheimer's disease. Brain Pathol 9: 133-146, 1999.
203. Markesbery WR, Lovell MA. Four-hydroxynon-enal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging 19: 33-36, 1998.
204. Martinez-Senac MD, Villalain J, Gomez-Fernandez JC. Structure of the Alzheimer beta-amyloid peptide (25-35) and its interaction with negatively charged phospholipid vesicles. Eur J Biochem 265: 744-753, 1999.
205. Matsuzaki K. Physicochemical interactions of amyloid (3-peptide with lipid bilayers. BBA Biomembranes 1768: 1935-1942, 2007.
206. Matsuzaki K, Horikiri C. Interactions of amyloid beta-peptide (1-40) with ganglioside-containing membranes. Biochemistry 38: 4137-4142, 1999.
207. Matsuzaki K, Noguch T, Wakabayashi M, Ikeda K, Okada T, Ohashi Y, Hoshino M, Naiki H. Inhibitors of amyloid beta-protein aggregation mediated by GM1-containing raft-like membranes. BBA Biomembranes 1768: 122-130, 2007.
208. Mattson MP, Cheng B, Culwell AR, Esch FS, Lieberburg I, Rydel RE. Evidence for excitopro-tective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein. Neuron 10: 243-254, 1993.
209. Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE. 3-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 12: 376-389, 1992.
210. McGrath LT, McGleenon BM, Brennan S, McColl D, McIlroy S, Passmore AP. Increased oxidative stress in Alzheimer's disease as assessed with 4-hydroxynonenal but not malondialdehyde. QJM 94: 485-490, 2001.
211. McIntosh LJ, Trush MA, Troncoso JC. Increased susceptibility of Alzheimer's disease temporal cortex to oxygen free radical-mediated processes. Free Radic Biol Med 23: 183-190, 1997.
212. McLaurin J, Chakrabartty A. Membrane disruption by Alzheimer beta-amyloid peptides mediated through specific finding to either phospholipids or gangliosides: implications for neurotoxicity. J Biol Chem 271: 26482-26489, 1996.
213. McLaurin J, Chakrabartty A. Characterization of the interactions of Alzheimer beta-amyloid peptides with phospholipid membranes. Eur J Biochem 245: 355-363, 1997.
214. McLaurin J, Darabie AA, Morrison MR. Cholesterol, a modulator of membrane-associated A beta-fibrillogenesis. Alz Dis Vasc Etiol Path 977: 376-383, 2002.
215. McLaurin J, Franklin T, Fraser PE, Chakrabartty A. Structural transitions associated with the interaction of Alzheimer beta-amyloid peptides with gangliosides. J Biol Chem 273: 4506-4515, 1998.
216. Minton AP. Implications of macromolecular crowding for protein assembly. Curr Opin Struct Biol 10: 34-39, 2000.
217. Miyata M, Smith JD. Apolipoprotein E allele-spe-cific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Gen 14: 55-61, 1996.
218. Molander-Melin M, Blennow K, Bogdanovic N, Dellheden B, Mansson JE, Fredman P. Structural membrane alterations in Alzheimer brains found to be associated with regional disease development; increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergent-resistant membrane domains. J Neurochem 92: 171-182, 2005.
219. Monji A, Utsumi H, Ueda T, Imoto T, Yoshida I, Hashioka S, Tashiro K, Tashiro N. The relationship between the aggregational state of the amyloid-beta peptides and free radical generation by the peptides. J Neurochem 77: 1425-1432, 2001.
220. Montine TJ, Neely MD, Quinn JF, Beal MF, Markesbery WR, Roberts LJ, Morrow JD. Lipid peroxidation in aging brain and Alzheimer's disease. Free Radic Biol Med 33: 620-626, 2002.
221. Montine TJ, Quinn JF, Milatovic D, Silbert LC, Dang T, Sanchez S, Terry E, Roberts LJ, Kaye JA, Morrow JD. Peripheral F-2-isoprostanes and F-4-neuroprostanes are not increased in Alzheimer's disease. Ann Neurol 52: 175-179, 2002.
222. Morandat S, Bortolato M, Anker G, Doutheau A, Lagarde M, Chauvet JP, Roux B. Plasmalogens protect unsaturated lipids against UV-induced oxidation in monolayer. Biochim Biophys Acta 1616: 137-146, 2003.
223. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Wilson RS, Aggarwal N, Schneider J. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 60: 940-946, 2003.
224. Morris MC, Evans DA, Tangney CC, Bienias JL, Wilson RS. Fish consumption and cognitive decline with age in a large community study. Arch Neurol 62: 1849-1853, 2005.
225. Morrow JD, Awad JA, Boss HJ, Blair IA, Roberts LJ, II. Non-cyclooxygenase-derived prostanoids (F2-Isoprostanes) are formed in situ on phosph-lipids. Proc Natl Acad Sci USA 89: 10721-10725, 1992.
226. Morrow JD, Minton TA, Mukundan CR, Campbell MD, Zackert WE, Daniel VC, Badr KF, Blair IA, Roberts LJ Free radical-induced generation of isoprostanes in vivo. J Biol Chem 269: 4317- 4326, 1994.
227. Mulder C, Wahlund LO, Teerlink T, Blomberg M, Veerhuis R, van Kamp GJ, Scheltens P, Scheffer PG. Decreased lysophosphatidylcholine/phos-phatidylcholine ratio in cerebrospinal fluid in Alzheimer's disease. J Neural Transm 110: 949-955, 2003.
228. Munishkina LA, Cooper EM, Uversky VN, Fink AL. The effect of macromolecular crowding on protein aggregation and amyloid fibril formation. J Mol Recognit 17: 456-464, 2004.
229. Murphy EJ, Huang HM, Cowburn RF, Lannfeltd L, Gibson GE. Phospholipid mass is increased in fibroblasts bearing the Swedish amyloid precursor mutation. Brain Res Bull 69: 79-85, 2006.
230. Murphy RC. Free-radical-induced oxidation of arachidonoyl plasmalogen phospholipids: antiox-idant mechanism and precursor pathway for bio-active eicosanoids. Chem Res Tox 14: 463-472, 2001.
231. Murray IVJ, Liu L, Komatsu H, Uryu K, Xiao G, Lawson JA, Axelsen PH. Membrane mediated amyloidogenesis and the promotion of oxidative lipid damage by amyloid beta proteins. J Biol Chem 282: 9335-9345, 2007.
232. Murray IVJ, Sindoni ME, Axelsen PH. Promotion of oxidative lipid membrane damage by amyloid beta proteins. Biochemistry 44: 12606-12613, 2005.
233. Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K. Apolipoprotein-E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimers-disease and Kuru plaque amyloid In Creutzfeldt-Jakob disease. Brain Res 541: 163-166, 1991.
234. Natte R, Yamaguchi H, Maat-Schieman MLC, Prins FA, Neeskens P, Roos RAC, van Duinen SG. Ultrastructural evidence of early non-fibrillar A beta 42 in the capillary basement membrane of patients with hereditary cerebral hemorrhage with amyloidosis, Dutch type. Acta Neuropathol (Berl) 98: 577-582, 1999.
235. Nelson TJ, Alkon DL. Oxidation of cholesterol by amyloid precursor protein and beta-amyloid pep-tide. J Biol Chem 280: 7377-7387, 2005.
236. Nunomura A, Perry G, Pappolla MA, Friedland RP, Hirai K, Chiba S, Smith MA. Neuronal oxida-tive stress precedes amyloid-beta deposition in Down syndrome. J Neuropath Exp Neurol 59: 1011-1017, 2000.
237. Nurk E, Drevon CA, Refsum H, Solvoll K, Vollset SE, Nygard O, Nygaard HA, Engedal K, Tell GS, Smith AD. Cognitive performance among the elderly and dietary fish intake: the Hordaland Health Study. Am J Clin Nutr 86: 1470-1478, 2007.
238. O'Nuallain B, Shivaprasad S, Kheterpal I, Wetzel R. Thermodynamics of A beta(1-40) amyloid fibril elongation. Biochemistry 44: 12709-12718, 2005.
239. Okada T, Ikeda K, Wakabayashi M, Ogawa M, Matsuzaki K. Formation of toxic A beta(1-40) fibrils on GM1 ganglioside-containing membranes mimicking lipid rafts: polymorphisms in A beta(1-40) fibrils. J Mol Biol 382: 1066-1074, 2008.
240. Okada T, Wakabayashi M, Ikeda K, Matsuzaki K. Formation of toxic fibrils of Alzheimer's amyloid beta-protein-(1-40) by monosialoganglioside GM1, a neuronal membrane component. J Mol Biol 371: 481-489, 2007.
241. Opazo C, Huang XD, Cherny RA, Moir RD, Ro-her AE, White AR, Cappai R, Masters CL, Tanzi RE, Inestrosa NC, Bush AI. Metalloenzyme-like activity of Alzheimer's disease beta-amyloid- Cu-de-pendent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H2O2. J Biol Chem 277: 40302-40308, 2002.
242. Paltauf F. Ether lipids in biomembranes. Chem Phys Lipids 74: 101-139, 1994.
243. Pamplona R, Dalfo E, Ayala VR, Bellmunt MJ, Prat J, Ferrer I, Portero-Otin M. Proteins in human brain cortex are modified by oxidation, glycoxi-dation, and lipoxidation: effects of Alzheimer disease and identification of lipoxidation targets. J Biol Chem 280: 21522-21530, 2005.
244. Patrono C, FitzGerald GA. Isoprostanes: potential markers of oxidant stress in atherothrom-botic disease. Arterioscler Thromb Vasc Biol 17: 2309-2315, 1997.
245. Permanne B, Perez C, Soto C, Frangione B, Wis-niewski T. Detection of apolipoprotein E dimeric soluble amyloid beta complexes in Alzheimer's disease brain supernatants. Biochem Biophys Res Commun 240: 715-720, 1997.
246. Petersen CAH, Alikhani N, Behbahani H, Wie-hager B, Pavlov PF, Alafuzoff I, Leinonen V, Ito A, Winblad B, Glaser E, Ankarcrona M. The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mi-tochondrial cristae. Proc Natl Acad Sci USA 105: 13145-13150, 2008.
247. Pettegrew JW, Panchalingam K, Hamilton RL, McClure RJ. Brain membrane phospholipid alterations in Alzheimer's disease. Neurochem Res 26: 771-782, 2001.
248. Pike CJ, RamezanArab N, Cotman CW. Beta-amyloid neurotoxicity in vitro: evidence of oxida-tive stress but not protection by antioxidants. J Neurochem 69: 1601-1611, 1997.
249. Pillot T, Goethals M, Vanloo B, Talussot C, Bras-seur R, Vandekerckhove J, Rosseneu M, Lins L. Fusogenic properties of the C-terminal domain of the Alzheimer beta-amyloid peptide. J Biol Chem 271: 28757-28765, 1996.
250. Plourde M, Fortier M, Vandal M, Tremblay-Mercier J, Freemantle E, Begin M, Pifferi F, Cunnane SC. Unresolved issues in the link between docosahexaenoic acid and Alzheimer's disease. Prost Leuk Essen Fatty Acids 77: 301- 308, 2007.
251. Pollard HB, Arispe N, Rojas E. Ion channel hypothesis for Alzheimer amyloid peptide neuro-toxicity. Cell Molec Neurobiol 15: 513-526, 1995.
252. Prasad MR, Lovell MA, Yatin M, Dhillon H, Markesbery WR. Regional membrane phospho-lipid alterations in Alzheimer's disease. Neuro-chem Res 23: 81-88, 1998.
253. Pratico D, Clark CM, Lee VMY, Trojanowski JQ, Rokach J, FitzGerald GA. Increased 8,12-iso-iPF(2 alpha)-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol 48: 809-812, 2000.
254. Pratico D, Delanty N. Oxidative injury in diseases of the central nervous system: focus on Alzheimer's disease. Am J Med 109: 577-585, 2000.
255. Pratico D, Lee VMY, Trojanowski JQ, Rokach J, FitzGerald GA. Increased F-2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J 12: 1777-1783, 1998.
256. Pratico D, Uryu K, Leight S, Trojanowswki JQ, Lee VMY. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci 21: 4183-4187, 2001.
257. Puglielli L, Friedlich AL, Setchell KDR, Nagano S, Opazo C, Cherny RA, Barnham KJ, Wade JD, Melov S, Kovacs DM, Bush AI. Alzheimer disease 3-amyloid activity mimics cholesterol oxidase. J Clin Invest 115: 2556-2563, 2005.
258. Qahwash IM, Boire A, Lanning J, Krausz T, Pytel P, Meredith SC. Site-specific effects of peptide lipidation on beta-amyloid aggregation and cytotoxicity. J Biol Chem 282: 36987-36997, 2007.
259. Quist A, Doudevski L, Lin H, Azimova R, Ng D, Frangione B, Kagan B, Ghiso J, Lal R. Amyloid ion channels: a common structural link for protein-misfolding disease. Proc Natl Acad Sci USA 102: 10427-10432, 2005.
260. Rajendran L, Schneider A, Schlechtingen G, Weidlich S, Ries J, Braxmeier T, Schwille P, Schulz JB, Schroeder C, Simons M, Jennings G, Knolker HJ, Simons K. Efficient inhibition of the Alzheimer's disease 3-secretase by membrane targeting. Science 320: 520-523, 2008.
261. Rangachari V, Moore BD, Reed DK, Sonoda LK, Bridges AW, Conboy E, Hartigan D, Rosenberry TL. Amyloid-3(1-42) rapidly forms protofibrils and oligomers by distinct pathways in low concentrations of sodium dodecylsulfate. Biochemistry 46: 12451-12462, 2007.
262. Reddy PH. Amyloid beta, mitochondrial structural and functional dynamics in Alzheimer's disease. Exp Neurol 218: 286-292, 2009.
263. Refolo LM, Pappolla MA, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, Sambam-urti K, Duff K. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 7: 321-331, 2000.
264. Reiss D, Beyer K, Engelmann B. Delayed oxidative degradation of polyunsaturated diacyl phospholipids in the presence of plasmalogen phospholipids in vitro. Biochem J 323: 807-814, 1997.
265. Relini A, Cavalleri O, Rolandi R, Gliozzi A. The two-fold aspect of the interplay of amyloidogenic proteins with lipid membranes. Chem Phys Lipids 158: 1-9, 2009.
266. Roberts LJ, Fessel JP. The biochemistry of the isoprostane, neuroprostane, and isofuran pathways of lipid peroxidation. Chem Phys Lipids 128: 173-186, 2004.
267. Roberts LJ, Montine TJ, Markesbery WR, Tapper AR, Hardy P, Chemtob S, Dettbarn WD, Morrow JD. Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J Biol Chem 273: 13605-13612, 1998.
268. Roberts LJ, II, Morrow JD. IsoProstanes: novel markers of endogenous lipid peroxidation and potential mediators of oxidant injury. Ann NY Acad Sci 744: 237-242, 1994.
269. Roheim PS, Carey M, Forte T, Vega GL. Apolipo-proteins in human cerebrospinal fluid. Proc Natl Acad Sci USA 76: 4646-4649, 1979.
270. Rottkamp CA, Nunomura A, Raina AK, Sayre LM, Perry G, Smith MA. Oxidative stress, antioxidants, and Alzheimer disease. Alzheimer Dis Assoc Disord 14, Suppl 1: S62-S66, 2000.
271. Sanan DA, Weisgraber KH, Russell SJ, Mahley RW, Huang D, Saunders A, Schmechel D, Wis-niewski T, Frangione B, Roses AD, Strittmatter WJ. Apolipoprotein-E associates with beta-amyloid peptide of Alzheimers-disease to form novel monofibrils: isoform Apoe4 associates more Efficiently than Apoe3. J Clin Invest 94: 860-869, 1994.
272. Sarell CJ, Syme CD, Rigby SEJ, Viles JH. Copper(II) binding to amyloid-beta fibrils of Alzheimer's disease reveals a picomolar affinity: stoichiometry and coordination geometry are independent of A beta oligomeric form. Biochemistry 48: 4388-4402, 2009.
273. Sayre LM, Perry G, Harris PLR, Liu YH, Schubert KA, Smith MA. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J Neurochem 74: 270-279, 2000.
274. Sayre LM, Zelasko DA, Harris PLR, Perry G, Salomon RG, Smith MA. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem 68: 2092-2097, 1997.
275. Schaefer EJ, Bongard V, Beiser AS, Lamon-Fava S, Robins SJ, Au R, Tucker KL, Kyle DJ, Wilson PWF, Wolf PA. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham heart study. Arch Neurol 63: 1545-1550, 2006.
276. Schauerte JA, Wong PT, Wisser KC, Ding H, Steel DG, Gafni A. Simultaneous single molecule fluorescence and conductivity studies reveal distinct classes of A3 species on lipid bilayers. Biochemistry 49: 3031-3039, 2010.
277. Schippling S, Kontush A, Arlt S, Buhmann C, Sturenburg HJ, Mann U, Muller-Thomsen T, Beisiegel U. Increased lipoprotein oxidation in Alzheimer's disease. Free Radic Biol Med 28: 351-360, 2000.
278. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Huletter CM, Joo SH, Pericakvance MA, Goldgaber D, Roses AD. Increased amyloid beta-peptide deposition in cerebral-cortex as a consequence of apolipoprotein-E genotype in late-onset Alzheimer-disease. Proc Natl Acad Sci USA 90: 9649-9653, 1993.
279. Schmitz C, Rutten BPF, Pielen A, Schafer S, Wirths O, Tremp G, Czech C, Blanchard V, Multhaup G, Rezaie P, Korr H, Steinbusch HWM, Pradier L, Bayer TA. Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease. Am J Pathol 164: 1495-1502, 2004.
280. Schneeweis LA, Koppaka V, Lund-Katz S, Phillips MC, Axelsen PH. Structural analysis of lipoprotein E particles. Biochemistry 44: 12525-12534, 2005.
281. Sengupta P, Garai K, Sahoo B, Shi Y, Callaway DJE, Maiti S. The amyloid beta peptide [A beta(1-40)] is thermodynamically soluble at physiological concentrations. Biochemistry 42: 10506-10513, 2003.
282. Shankar GM, Li SM, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14: 837-842, 2008.
283. Shao H, Jao S, Ma K, Zagorski MG. Solution structures of micelle-bound amyloid beta-(1-40) and beta-(1-42) peptides of Alzheimer's disease. J Mol Biol 285: 755-773, 1999.
284. + in a linear Bis-His coordination environment: insight into a possible neuroprotective mechanism for the amyloid-β peptide. J Am Chem Soc 130: 17826-17835, 2008.
285. Shin SJ, Lee SE, Boo JH, Kim M, Yoon YD, Kim SI, Mook-Jung I. Profiling proteins related to amyloid deposited brain of Tg2576 mice. Proteomics 4: 3359-3368, 2004.
286. Shringarpure R, Grune T, Sitte N, Davies KJA. 4-Hydroxynonenal-modified amyloid-beta peptide inhibits the proteasome: possible importance in Alzheimer's disease. Cell Mol Life Sci 57: 1802-1809, 2000.
287. Siegel SJ, Bieschke J, Powers ET, Kelly JW. The oxidative stress metabolite 4-hydroxynonenal promotes Alzheimer protofibril formation. Biochemistry 46: 1503-1510, 2007.
288. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 95: 6460-6464, 1998.
289. Sjogren M, Blennow K. The link between cholesterol and Alzheimer's disease. World J Biol Psych 6: 85-97, 2005.
290. 2+ induced aggregation and dityrosine formation of the Alzheimer's disease amyloid-3 peptide. Biochemistry 46: 2881-2891, 2007.
291. Smith DP, Smith DG, Curtain CC, Boas JF, Pil-brow JR, Ciccotosto GD, Lau TL, Tew DJ, Perez K, Wade JD, Bush AI, Drew SC, Separovic F, Masters CL, Cappai R, Barnham KJ. Copper mediated amyloid-beta toxicity is associated with an intermolecular histidine bridge. J Biol Chem 281: 15145-15154, 2006.
292. Smith MA, Casadesus G, Joseph JA, Perry G. Amyloid-beta and tau serve antioxidant functions in the aging and Alzheimer brain. Free Radic Biol Med 33: 1194-1199, 2002.
293. Smith MA, Harris PLR, Sayre LM, Beckman JS, Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 17: 2653-2657, 1997.
294. Smith MA, Hirai K, Hsiao K, Pappolla MA, Harris PLR, Siedlak SL, Tabaton M, Perry G. Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem 70: 2212-2215, 1998.
295. Smith MA, Perry G, Richey PL, Sayre LM, Anderson VE, Beal MF, Kowall N. Oxidative damage in Alzheimer's. Nature 382: 120-121, 1996.
296. Smith MA, Taneda S, Richey PL, Miyata S, Yan SD, Stern D, Sayre LM, Monnier VM, Perry G. Advanced Maillard reaction end-products are associated with Alzheimer-disease pathology. Proc Natl Acad Sci USA 91: 5710-5714, 1994.
297. Sokolov Y, Kozak JA, Kayed R, Chanturiya A, Glabe C, Hall JE. Soluble amyloid oligomers increase bilayer conductance by altering dielectric structure. J Gen Physiol 128: 637-647, 2006.
298. Song WL, Lawson JA, Reilly D, Rokach J, Chang CT, Giasson B, FitzGerald GA. Neurofurans, novel indices of oxidant stress derived from docosahexaenoic acid. J Biol Chem 283: 6-16, 2008.
299. Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, Hyman B, Burton MA, Goldstein LE, Duong S, Tanzi RE, Moir RD. The Alzheimer's disease-associated amyloid 3-protein is an antimicrobial peptide. PLoS ONE 5: e9505, 2010.
300. Sparks DL, Scheff SW, Hunsaker JC, Liu HC, Landers T, Gross DR. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary-cholesterol. Exp Neurol 126: 88-94, 1994.
301. Stewart CR, Wilson LM, Zhang Q, Pham CLL, Waddington LJ, Staples MK, Stapleton D, Kelly JW, Howlett GJ. Oxidized cholesterol metabolites found in human atherosclerotic lesions promote apolipoprotein C-II amyloid fibril formation. Biochemistry 46: 5552-5561, 2007.
302. Stokin GB, Lillo C, Falzone TL, Brusch RG, Rock-enstein E, Mount SL, Raman R, Davies P, Masliah E, Williams DS, Goldstein LSB. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science 307: 1282-1288, 2005.
303. Stratman NC, Castle CK, Taylor BM, Epps DE, Melchior GW, Carter DB. Isoform-specific interactions of human apolipoprotein E to an intermediate conformation of human Alzheimer amyloid-beta peptide. Chem Phys Lipids 137: 52-61, 2005.
304. Strausak D, Mercer JFB, Dieter HH, Stremmel W, Multhaup G. Copper in disorders with neurological symptoms: Alzheimer's, Menkes, and Wilson diseases. Brain Res Bull 55: 175-185, 2001.
305. Streltsov VA. X-ray absorption and diffraction studies of the metal binding sites in amyloid be-ta-peptide. Eur Biophys J 37: 257-263, 2008.
306. Streltsov VA, Titmuss SJ, Epa VC, Barnham KJ, Masters CL, Varghese JN. The structure of the amyloid-beta peptide high-affinity copper II binding site in Alzheimer disease. Biophys J 95: 3447-3456, 2008.
307. Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericakvance M, Sch-mechel D, Saunders AM, Goldgaber D, Roses AD. Binding of human apolipoprotein-E to synthetic amyloid-beta peptide: isoform-specific effects and implications for late-onset Alzheimer-disease. Proc Natl Acad Sci USA 90: 8098-8102, 1993.
308. Subasinghe S, Unabia S, Barrow CJ, Mok SS, Aguilar MI, Small DH. Cholesterol is necessary both for the toxic effect of A beta peptides on vascular smooth muscle cells and for A beta binding to vascular smooth muscle cell membranes. J Neurochem 84: 471-479, 2003.
309. Sultana R, Butterfield DA. Oxidatively modified GST and MRP1 in Alzheimer's disease brain: implications for accumulation of reactive lipid per-oxidation products. Neurochem Res 29: 2215-2220, 2004.
310. Surewicz WK, Mantsch HH. The conformation of dynorphin A-(1-13) in aqueous solution as studied by Fourier transform infrared spectroscopy. J Mol Struct 214, 143-147, 1989.
311. Svennerholm L, Gottfries CG. Membrane-lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form (type-I) and demyelination in late-onset form (type-II). J Neurochem 62: 1039-1047, 1994.
312. Tamaoka A, Miyatake F, Matsuno S, Ishii K, Na-gase S, Sahara N, Ono S, Mori H, Wakabayashi K, Tsuji S, Takahashi H, Shoji S. Apolipoprotein E allele-dependent antioxidant activity in brains with Alzheimer's disease. Neurol 54: 2319-2321, 2000.
313. Terzi E, Holzemann G, Seelig J. Alzheimer beta-amyloid peptide 25-35: electrostatic interactions with phospholipid membranes. Biochemistry 33: 7434-7441, 1994.
314. Terzi E, Holzemann G, Seelig J. Self-association of beta-amyloid peptide (1-40) in solution and binding to lipid membranes. J Mol Biol 252: 633- 642, 1995.
315. Terzi E, Holzemann G, Seelig J. Interaction of Alzheimer beta-amyloid peptide(1-40) with lipid membranes. Biochemistry 36: 14845-14852, 1997.
316. Tickler AK, Smith DG, Ciccotosto GD, Tew DJ, Curtain CC, Carrington D, Masters CL, Bush AI, Cherny RA, Cappai R, Wade JD, Barnham KJ. Methylation of the imidazole side chains of the Alzheimer disease amyloid-3 peptide results in abolition of superoxide dismutase-like structures and inhibition of neurotoxicity. J Biol Chem 280: 13355-13363, 2005.
317. Tien M, Berlett BS, Levine RL, Chock PB, Stadt-man ER. Peroxynitrite-mediated modification of proteins at physiological carbon dioxide concentration: pH dependence of carbonyl formation, tyrosine nitration, and methionine oxidation. Proc Natl Acad Sci USA 96: 7809-7814, 1999.
318. Tomiyama T, Matsuyama S, Iso H, Umeda T, Ta-kuma H, Ohnishi K, Ishibashi K, Teraoka R, Sakama N, Yamashita T, Nishitsuji K, Ito K, Shi-mada H, Lambert MP, Klein WL, Mori H. A mouse model of amyloid 3 oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J Neurosci 30: 4845-4856, 2010.
319. Torp R, Head E, Milgram NW, Hahn F, Ottersen OP, Cotman CW. Ultrastructural evidence of fibrillar beta-amyloid associated with neuronal membranes in behaviorally characterized aged dog brains. Neuroscience 96: 495-506, 2000.
320. Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol 572: 477-492, 2006.
321. Treiber C, Quadir MA, Voigt P, Radowski M, Xu SJ, Munter LM, Bayer TA, Schaefer M, Haag R, Multhaup G. Cellular copper import by nanocar-rier systems, intracellular availability, and effects on amyloid beta peptide secretion. Biochemistry 48: 4273-4284, 2009.
322. Trojanowski JQ, Lee VM. The role of tau in Alzheimer's disease. Med Clin North Am 86: 615-627, 2002.
323. Tully AM, Roche HM, Doyle R, Fallon C, Bruce I, Lawlor B, Coakley D, Gibney MJ. Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer's disease: a case-control study. Br J Nutr 89: 483-489, 2003.
324. Uchida K. Current status of acrolein as a lipid peroxidation product. Trends Cardiovasc Med 9: 109-113, 1999.
325. Uchida K. 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog Lipid Res 42: 318-343, 2003.
326. Uchida K, Kanematsu M, Morimitsu Y, Osawa T, Noguchi N, Niki E. Acrolein is a product of lipid peroxidation reaction: formation of free acrolein and its conjugate with lysine residues in oxidized low density lipoproteins. J Biol Chem 273: 16058-16066, 1998.
327. Uchida K, Kanematsu M, Sakai K, Matsuda T, Hattori N, Mizuno Y, Suzuki D, Miyata T, Noguchi N, Niki E, Osawa T. Protein-bound acrolein: potential markers for oxidative stress. Proc Natl Acad Sci USA 95: 4882-4887, 1998.
328. Uchida K, Stadtman ER. Modification of histidine-residues in proteins by reaction with 4-hy-droxynonenal. Proc Natl Acad Sci USA 89: 4544-4548, 1992.
329. Usui K, Hulleman JD, Paulsson JF, Siegel SJ, Powers ET, Kelly JW. Site-specific modification of Alzheimer's peptides by cholesterol oxidation products enhances aggregation energetics and neurotoxicity. Proc Natl Acad Sci USA 106: 18563-18568, 2009.
330. Van Nostrand WE, Melchor JP, Ruffini L. Pathologic amyloid beta-protein cell surface fibril assembly on cultured human cerebrovascular smooth muscle cells. J Neurochem 70: 216-223, 1998.
331. Varadarajan S, Yatin S, Aksenova M, Butterfield DA. Alzheimer's amyloid beta-peptide-associ-ated free radical oxidative stress and neurotoxicity. J Struct Biol 130: 184-208, 2000.
332. Varadarajan S, Yatin S, Butterfield DA. Alzheimer's amyloid beta peptide (1-42) fibrils are not always neurotoxic. Alzheimers Rep 3: 71-76, 2000.
333. Wahrle SE, Jiang H, Parsadanian M, Hartman RE, Bales KR, Paul SM, Holtzman DM. Deletion of Abca1 increases A beta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J Biol Chem 280: 43236-43242, 2005.
334. Wakabayashi M, Matsuzaki K. Formation of amyloids by a beta-(1-42) on NGF-differentiated PC12 cells: roles of gangliosides and cholesterol. J Mol Biol 371: 924-933, 2007.
335. Wakabayashi M, Okada T, Kozutsumi Y, Matsuzaki K. GM1 ganglioside-mediated accumulation of amyloid beta-protein on cell membranes. Biochem Biophys Res Commun 328: 1019-1023, 2005.
336. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416: 535-539, 2002.
337. Walsh DM, Lomakin A, Benedek GB, Condron MM, Teplow DB. Amyloid beta-protein fibrillo-genesis: detection of a protofibrillar intermediate. J Biol Chem 272: 22364-22372, 1997.
338. Wang SSS, Rymer DL, Good TA. Reduction in cholesterol and sialic acid content protects cells from the toxic effects of beta-amyloid peptides. J Biol Chem 276: 42027-42034, 2001.
339. Waschuk SA, Elton EA, Darabie AA, Fraser PE, McLaurin J. Cellular membrane composition defines Abeta-lipid interactions. J Biol Chem 276: 33561-33568, 2001.
340. Weisgraber KH, Shinto LH. Identification of the disulfide-linked homodimer of apolipoprotein E3 in plasma: impact on receptor-binding activity. J Biol Chem 266: 12029-12034, 1991.
341. Widenbrant MJO, Rajadas J, Sutardja C, Fuller GG. Lipid-induced 3-amyloid peptide assemblage fragmentation. Biophys J 91: 4071-4080, 2006.
342. Williams TI, Lynn BC, Markesbery WR, Lovell MA. Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in mild cognitive impairment and early Alzheimer's disease. Neurobiol Aging 27: 1094-1099, 2006.
343. Wisniewski T, Castano EM, Golabek A, Vogel T, Frangione B. Acceleration of Alzheimers fibril formation by apolipoprotein-E in-vitro. Am J Pathol 145: 1030-1035, 1994.
344. Wong PT, Schauerte JA, Wisser KC, Ding H, Lee EL, Steel DG, Gafni A. Amyloid-beta membrane binding and permeabilization are distinct processes influenced separately by membrane charge and fluidity. J Mol Biol 386: 81-96, 2009.
345. Wu Y, Luo Y. Transgenic C. elegans as a model in Alzheimer's research. Curr Alzheimer Res 2: 37-47, 2005.
346. Yamaguchi H, Maat-Schieman MLC, van Duinen SG, Prins FA, Neeskens P, Natte R, Roos RAC. Amyloid beta protein (A beta) starts to deposit as plasma membrane-bound form in diffuse plaques of brains from hereditary cerebral hemorrhage with amyloidosis-Dutch type, Alzheimer disease and nondemented aged subjects. J Neuropath Exp Neurol 59: 723-732, 2000.
347. Yamazaki T, Chang TY, Haass C, Ihara Y. Accumulation and aggregation of amyloid beta-protein in late endosomes of Niemann-Pick type C cells. J Biol Chem 276: 4454-4460, 2001.
348. Yanagisawa K, Odaka A, Suzuki N, Ihara Y. GM1 ganglioside-bound amyloid beta-protein (A beta): a possible form of preamyloid in Alzheimer's disease. Nat Med 1: 1062-1066, 1995.
349. Yang DS, Smith JD, Zhou ZM, Gandy SE, Martins RN. Characterization of the binding of amyloid-beta peptide to cell culture-derived native apoli-poprotein E2, E3, and E4 isoforms and to isoforms from human plasma. J Neurochem 68: 721-725, 1997.
350. Yao JK, Wengenack TM, Curran GL, Poduslo JF. Reduced membrane lipids in the cortex of Alzheimer's disease transgenic mice. Neurochem Res 34: 102-108, 2009.
351. Yao ZX, Drieu K, Szweda LI, Papadopoulos V. Free radicals and lipid peroxidation do not mediate beta-amyloid-induced neuronal cell death. Brain Res 847: 203-210, 1999.
352. Yip CM, Darabie AA, McLaurin J. A beta 42-peptide assembly on lipid bilayers. J Mol Biol 318: 97-107, 2002.
353. Yip CM, McLaurin J. Amyloid-beta peptide assembly: a critical step in fibrillogenesis and membrane disruption. Biophys J 80: 1359-1371, 2001.
354. Yoshiike Y, Kayed R, Milton SC, Takashima A, Glabe CG. Pore-forming proteins share structural and functional homology with amyloid oligomers. Neuromol Med 9: 270-275, 2007.
355. Yoshiike Y, Tanemura K, Murayama O, Akagi T, Murayama M, Sato S, Sun XY, Tanaka N, Takashima A. New insights on how metals disrupt amyloid beta-aggregation and their effects on amyloid-beta cytotoxicity. J Biol Chem 276: 32293-32299, 2001.
356. Yoshimoto N, Tasaki M, Shimanouchi T, Umako-shi H, Kuboi R. Oxidation of cholesterol catalyzed by amyloid beta-peptide (A beta)-Cu complex on lipid membrane. J Biosci Bioeng 100: 455-459, 2005.
357. Zagol-Ikapitte I, Masterson TS, Amarnath V, Montine TJ, Andreasson KI, Boutaud O, Oates JA. Prostaglandin H-2-derived adducts of proteins correlate with Alzheimer's disease severity. J Neurochem 94: 1140-1145, 2005.
358. Zaman Z, Roche S, Fielden P, Frost PG, Niriella DC, Cayley AC. Plasma concentrations of vitamins A and E and carotenoids in Alzheimer's disease. Age Ageing 21: 91-94, 1992.
359. Zerbinatti CV, Wahrle SE, Kim H, Cam JA, Bales K, Paul SM, Holtzman DM, Bu GJ. Apolipoprotein E and low density lipoprotein receptor-related protein facilitate intraneuronal A beta 42 accumulation in amyloid model mice. J Biol Chem 281: 36180-36186, 2006.
360. Zhang QH, Powers ET, Nieva J, Huff ME, Dendle MA, Bieschke J, Glabe CG, Eschenmoser A, Wentworth P, Lerner RA, Kelly JW. Metabolite-initiated protein misfolding may trigger Alzheimer's disease. Proc Natl Acad Sci USA 101: 4752-4757, 2004.
361. Zhou S, Zhou H, Walian PJ, Jap BK. Regulation of -y-secretase activity in Alzheimer's disease. Biochemistry 46: 2553-2563, 2007.
362. Zommara M, Tachibana N, Mitsui K, Nakatani N, Sakono M, Ikeda I, Imaizumi K. Inhibitory effect of ethanolamine plasmalogen on iron-dependent and copper-dependent lipid-peroxidation. Free Radic Biol Med 18: 599-602, 1995.
363. Zou K, Gong JS, Yanagisawa K, Michikawa M. A novel function of monomeric amyloid beta-protein serving as an antioxidant molecule against metal-induced oxidative damage. J Neurosci 22: 4833-4841, 2002.
364. Zubenko GS. Hippocampal membrane-alteration in Alzheimers-disease. Brain Res 385: 115-121, 1986.